-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A phase III clinical trial conducted by the Childhood Oncology Group showed that a combination of drugs is very effective for children with standard and high-risk acute promyelocytic leukemia (also known as APL)
child
Acute promyelocytic leukemia is a subtype of acute myeloid leukemia
APL is an acute leukemia, which means it develops rapidly and requires immediate treatment
diagnosis
The results of the trial were published in JAMA Oncology on November 11.
JAMA
In the trial, 154 children between the ages of 1 and 22 with a new diagnosis of standard or high-risk APL received oral all-trans retinoic acid and intravenous arsenic trioxide for at least 28 days
The two-year overall survival rates for children with standard and high-risk APL are 99% and 100%, respectively, and the event-free survival rates are 98% and 96%, respectively
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://